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Abstract
Background: Vitamin A supplementation of 6-59 month old children is currently recommended by the World
Health Organization based on evidence that it reduces mortality. There has been considerable interest in
determining the benefits of neonatal vitamin A supplementation, but the results of existing trials are conflicting. A
technical consultation convened by WHO pointed to the need for larger scale studies in Asia and Africa to inform
global policy on the use of neonatal vitamin A supplementation. Three trials were therefore initiated in Ghana,
India and Tanzania to determine if vitamin A supplementation (50,000 IU) given to neonates once orally on the
day of birth or within the next two days will reduce mortality in the period from supplementation to 6 months of
age compared to placebo.
Methods/Design: The trials are individually randomized, double masked, and placebo controlled. The required
sample size is 40,200 in India and 32,000 each in Ghana and Tanzania. The study participants are neonates who
fulfil age eligibility, whose families are likely to stay in the study area for the next 6 months, who are able to feed
orally, and whose parent(s) provide informed written consent to participate in the study. Neonates randomized to
the intervention group receive 50,000 IU vitamin A and the ones randomized to the control group receive placebo
at the time of enrolment. Mortality and morbidity information are collected through periodic home visits by a
study worker during infancy. The primary outcome of the study is mortality from supplementation to 6 months of
age. The secondary outcome of the study is mortality from supplementation to 12 months of age. The three
studies will be analysed independent of each other. Subgroup analysis will be carried out to determine the effect
by birth weight, sex, and timing of DTP vaccine, socioeconomic groups and maternal large-dose vitamin A
supplementation.
Discussion: The three ongoing studies are the largest studies evaluating the efficacy of vitamin A supplementation
to neonates. Policy formulation will be based on the results of efficacy of the intervention from the ongoing
randomized controlled trials combined with results of previous studies.
Trial Registration: Ghana: Australian New Zealand Clinical Trials Registry (ANZCTR) - ACTRN12610000582055;
India: CLINICALTRIALS.GOV - NCT01138449; Tanzania: Australian New Zealand Clinical Trials Registry (ANZCTR) -
ACTRN12610000636055.
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Full list of author information is available at the end of the article
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Background
Globally, about 9 million under five children die every
year, most of them in developing countries. About two
thirds of these deaths occur in the first year of life. The
global community is committed to reduce child mortal-
ity by two thirds between 1990 and 2015 (MDG4).
More than a third of child deaths have been attributed
to maternal and child under-nutrition [1].
Vitamin A deficiency increases the risk of disease and
death from severe infections in children. It is estimated
that vitamin A deficiency, defined as a low serum retinol
concentration (< 0.70 μmol/l), affects 190 million pre-
school-age children and 19.1 million pregnant women,
the majority in Africa and South-East Asia [2].
Three systematic reviews and meta-analysis of RCTs
indicate that vitamin A supplementation of 6-59 month
old children significantly reduces all-cause mortality in
this age group by about 23-30% [3-5]. Periodic high-
dose vitamin A supplementation at 6-59 months of age
is now recommended by the World Health Organization
(WHO) for the prevention of vitamin A deficiency and
for reducing the risk of death in children. However, vita-
min A supplementation for 1-5 month old infants has
not been shown to be beneficial in reducing infant mor-
tality and morbidity [6-9].
There has been considerable interest in research on
determining the benefits of vitamin A supplementation
of infants less than 1 month (neonatal supplementation),
but the results of randomized controlled trials evaluating
this intervention are conflicting. A technical consulta-
tion convened by WHO in December 2008 reviewed all
available evidence and recommended an additional set
of randomized placebo-controlled trials to generate the
evidence necessary to formulate policy for or against
neonatal vitamin A supplementation. Consequently,
WHO is coordinating three trials in Ghana, India and
Tanzania, to examine the efficacy and safety of neonatal
vitamin A supplementation. In this paper, we briefly
review the available evidence regarding neonatal vitamin
A supplementation, the ratio n a l ef o rt h et h r e eo n g o i n g
trials to address the current gap in knowledge, followed
by detailed presentation of the trials’ design and meth-
ods for field implementation and analyses.
A small study conducted in Indonesia in 1996 found
that 50,000 international units (IU) vitamin A given on
the first day of life resulted in a 64% reduction in infant
mortality [10]. Subsequent studies in Bangladesh and
India found that 50,000 IU vitamin A given in the first
two days after birth reduced mortality in the first 6
months by about 15-20% [11,12]. However, two other
studies conducted in Guinea-Bissau and Zimbabwe did
not find any reduction in mortality with the same inter-
vention [13,14].
A systematic review of literature [15] identified 6 trials
involving 42,508 infants. Their meta-analysis did not
find a significant overall effect of neonatal vitamin A
supplementation on mortality during first year of life
(Pooled relative risk 0.92, 95% CI 0.75 to 1.12, P =
0.393; random effects model). Some experts suggested
that the variability of effect sizes across neonatal trials is
explainable by the region in which the study was con-
ducted [16]. In the meta-regression conducted by Gogia
and Sachdev, region was not a significant predictor of
heterogeneity (P = 0.133) of results although the effect
sizes appeared disparate (RR 1.13, 95% CI 0.90 to 1.43
in Africa and 0.82, CI 0.66 to 1.02, in Asia). They con-
cluded that the trials were too small to make clear con-
clusions about regional differences and underlying
biological plausibility was uncertain.
I nar e c e n t l yp u b l i s h e ds t u d yf r o mG u i n e aB i s s a u ,
although there was no significant effect of neonatal vita-
min A supplementation on infant mortality, when pool-
ing the data with a prior study from the same setting, it
appeared that boys benefited but there was a signifi-
cantly harmful effect on girls’ survival [17]. However, in
a new meta-analysis of all published trials, including the
two studies from Guinea Bissau, there was no significant
difference in the effects of neonatal vitamin A supple-
mentation on mortality among boys and girls [18].
A technical consultation convened by WHO in Decem-
ber 2008 reviewed all available evidence and concluded
that there was insufficient evidence base currently avail-
able to make a public health recommendation for or
against neonatal vitamin A supplementation. The techni-
cal consultation recommended that additional randomized
placebo-controlled trials should be conducted. It was
recommended that these trials should be significantly lar-
ger than the previous trials and that they should ade-
quately represent the types of settings in which a
supplementation intervention would be considered, if pro-
ven to be efficacious. In January 2009, WHO sent out a
call for expressions of interest from study sites interested
in conducting randomized controlled trials in newborn
vitamin A supplementation. The three trials chosen in
Ghana, India and Tanzania are described in this paper.
Goal of the Ongoing Trials
The goal of these trials is to inform global policy on the
use of neonatal vitamin A supplementation for reducing
infant mortality in low- and middle-income countries,
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plementation with 50,000 IU vitamin A within the first
2-3 days after birth in low- and middle-income coun-
tries reduce the risk of death in the first six months of
life?
Objectives of each trial
The primary objective of these studies is:
■ To determine if vitamin A supplementation (50,000
IU) given to neonates once orally either on the day of
birth or in the next 2 days will reduce mortality in the
period from supplementation to 6 months of age by at
least 15% as compared to placebo.
The secondary objectives of the studies are:
■ To determine if vitamin A supplementation (50,000
IU) given to neonates once orally either on the day of
birth or in the next 2 days will reduce mortality in the
period from supplementation to 12 months of age.
■ To determine the efficacy of vitamin A supplemen-
tation (50,000 IU) given to neonates once orally either
on the day of birth or in the next 2 days in reducing
mortality in the period from supplementation to 28 days
of age.
■ To determine the efficacy of the above intervention
in reducing the incidence of severe morbidity defined as
hospitalizations due to any illness in the period from
supplementation to 6 months of age.
■ To document the potential adverse effects of vita-
min A such as bulging fontanelle, vomiting, irritability,
fever, diarrhoea, inability to suck or feed, convulsions or
any other condition that caused parents to be con-
cerned, in the 3 day period following administration of
the supplement.
■ To determine the vitamin A status of a subsample
of infants at 2 weeks and 3 months of age in the vitamin
A supplementation and placebo groups.
Methods/Design
The three trials in Ghana, India and Tanzania are inde-
pendent studies with the same study design, partici-
pants, intervention, comparison and outcomes, as well
as quality control and coordination mechanisms.
Overview of Study Design
The studies are individually randomized, double-masked,
placebo controlled trials. The study participants are neo-
n a t e sw h oa r el i k e l yt os t a yi nt h es t u d ya r e a su n t i la t
least 6 months of age, who are able to feed orally at the
time of enrolment and whose parents provide written
informed consent for study participation. Neonates ran-
domized to the intervention group receive 50,000 IU
vitamin A on the day of birth or in the next two days,
and those randomized to the control group receive pla-
cebo. Potential adverse events are determined during
visits by a study worker one day and three days after
supplementation. A potential adverse event is defined as
any harmful and/or undesired effect as reported by the
family which may have resulted from the use of the vita-
min A supplement. These include presence of bulging
fontanelle, vomiting, fever, diarrhoea, inability to suck or
feed, and convulsions. Mortality and morbidity informa-
tion are collected through periodic home visits by a
study worker during infancy (Figure 1).
Sample size
The infant mortality rate was estimated to be about 50
per 1000 live births in India and about 60 per 1000 in
Ghana and Tanzania. Assuming a 10% loss to follow up,
sample sizes at each site were calculated to detect a 15%
reduction in mortality from enrolment to 6 months of
age, which is the primary outcome, with 85% power and
a 5% significance level. The required sample size was
40,200 in India and 32,000 each in Ghana and Tanzania.
This sample size would also be enough to detect a dif-
ference of 15% in post-enrolment infant mortality and
20% in post-enrolment neonatal mortality (secondary
outcomes).
Blood samples are requested from 720 randomly
selected infants at 2 weeks of age and another 720 ran-
domly selected infants and their mothers at 3 months of
age at each site. This sample size is sufficient to detect
an increase of 0.25 standard deviation (SD) in mean
serum retinol in the intervention group after supple-
mentation, with 80% power in each site, and assuming
that about 30% families will refuse to allow collection of
blood samples.
Study approvals
All three study protocols were sent for scientific peer
review by WHO and the suggestions of the reviewers
were incorporated. The three study protocols were
reviewed and approved by the WHO Ethics Review
Committee. The Ghana protocol was additionally
approved by the Ghana Health Service Ethical Review
Committee and the ethics committees of the Kintampo
Health Research Centre, and the London School of
Hygiene and Tropical Medicine. The India protocol was
approved by the ethics committee of the Society for
Applied Studies and the state government. The Tanza-
nia protocol was approved by the Ifakara Health Insti-
tute ethics committee, the Tanzania National Institute
of Medical Research ethics committee and the Harvard
School of Public Health institutional review board.
Ethical issues
Communities in all sites were sensitized to the study
prior to randomization. This was achieved through
meetings with community leaders and with community
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of the parents for each neonate before he/she is enrolled
in the study. Any death within 72 hours of supplement
administration, irrespective of the cause and relationship
with supplementation, is communicated to WHO by the
site investigators within 10 days of the team member
becoming aware of the event. WHO communicates this
information to the Data Safety Monitoring Board
(DSMB). The DSMB reviews this information every 3
months, and all the collected data every six months to
d e t e r m i n ei ft h es t u d ys h o u l db ec o n t i n u e do rs t o p p e d ,
based on pre-decided stopping rules.
Randomization
The unit of randomization is the individual infants.
Three separate randomization schemes in blocks of size
20 are being used to allocate infants to intervention or
placebo group at the three sites. The randomization lists
were prepared off-site, under the responsibility of
WHO. Until the close of the trial, the code will be avail-
able only to the DSMB.
Study intervention preparation, masking and
administration
A manufacturer (Strides Arcolab Limited, Bangalore,
India) was identified to supply the capsules for the study
in two batches. The active ingredients in the vitamin A
capsules were retinol palmitate (50,000 IU) and minute
amounts of vitamin E, whereas the placebo capsules
contained soybean oil. The vitamin A and placebo cap-
sules appear identical in colour, shape, and size. Cap-
sules were individually packed in blister packs with two
capsules, one for the dose and the other for the backup
dose. A backup dose is provided in case of accidental
spillage during administration of the main dose.
Labels were printed at WHO, Geneva, with study site
and infant number in sequence (e.g. 100001 was the
first number for Ghana, 200001 the first number for
India and 300001 the first number for Tanzania). The
labels with infant numbers allocated to the intervention
group in the randomization list were fixed on capsules
containing vitamin A and those allocated to the placebo
group were fixed on blisters containing placebo capsules
 
   
   
 
 
 
 
 
 
 
 
 
 
Identification of newborns as soon as possible after birth 
Screening for eligibility 
Written, informed consent for study participation   
Enrolment and administration of vitamin A/placebo supplement on the day of birth or in the 
next two days 
Follow Up 
  Periodic visits during infancy to document vital status, hospitalizations, feeding, 
immunizations  
  Blood specimen in subsample of enrolled infants at 2 wk and of mother-infant pairs at 3 
months  of age 
Visits for monitoring potential adverse events 1 and 3 days after supplementation 
Figure 1 Outline of implementation strategy common to the three studies.
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capsules for only one treatment arm were labelled in the
packing room. When labelling and packing for the first
arm was completed, the labelled blisters were placed in
sealed labelled boxes and removed from the packing
room before the next treatment arm capsules were
brought into the room. The research teams and parents
are thus completely unaware of the content of the cap-
sules, which were only labelled with the study site and
infant number.
The supplement is administered on the day of birth or
in the next 2 days with a minimum period of 2 hours
between birth and dosing so as not to interfere with
immediate newborn care and to ensure that the infant’s
condition is stable. The supplement capsule is snipped
with scissors near the end of the nipple and the com-
plete contents are squeezed directly into the neonate’s
mouth. The backup neonate dose is administered only if
the worker drops the contents accidentally after cutting
the tip.
Site description and implementation strategy of the three
studies
Ghana
Study setting The study area comprises 7 contiguous
districts (Kintampo North, Kintampo South, Wenchi,
Tain, Techiman, Nkoranza North and Nkoranza South)
in the Brong Ahafo region of central rural Ghana, and
covers 12,000 square kilometres. The study population
is estimated at 600,000 and includes approximately
120,000 women of reproductive age and 15,000 live
births per year. Approximately 30% of deliveries occur
at home, 40% in the 4 major hospitals and the remain-
ing 20% in a wide range of private maternity homes and
small health centres across the districts. This area has a
low HIV prevalence (2.6% in women attending antenatal
care in 2006) and an infant mortality rate of about 60
per 1000 live births [19]. Data from previous studies in
this region of Ghana indicate a Vitamin A Deficiency
problem of public health significance in the area: 27.2%
of 9 month old infants had serum retinol < 20 μg/dl of
age [20] and 15% of pregnant women attending antena-
tal clinics had serum retinol < 20 μg/dl [21].
Identification of newborns Village based field workers
(FWs) have enumerated all houses or “compounds” in
the study area and visit all reproductive age women
every 3 months to identify pregnant women. Pregnant
women are followed up to enable the study team to
reach neonates as soon as possible after birth. The
families of pregnant women are encouraged to report
the birth to the study team as soon as possible, irrespec-
tive of the place of birth. Other study staff, called dosing
supervisors, based in the 4 major hospitals screen all
babies who are residents in the study area as soon as
possible after birth for enrolment in the study. They
work in close collaboration with the hospital nurses and
this is an efficient method of identifying the births in
the 4 major hospitals early after birth. Other dosing
supervisors visit all small health centres and private
maternity homes and key informants (e.g. traditional
birth attendants, village based FWs) in the study area
daily to identify births.
Screening and enrolment The dosing supervisors assess
the newborns for eligibility either in health facilities or
at home. They administer the informed consent form to
parents of eligible infants. They also complete a ques-
tionnaire with baseline characteristics of the mother and
the family. If parents provide consent for participation
of their infants in the study, the dosing supervisors allo-
cate the next available infant number to the infant and
administer the study supplement with this number. The
infant is weighed and information on maternal diet,
including maternal vitamin A supplementation is
collected.
Monitoring of potential adverse events The dosing
supervisors document any potential adverse events by
visits at 1 and 3 days after supplementation. While most
of these visits occur at home, some are conducted in
health facilities if the mother and infant are not yet dis-
charged after a facility birth. In addition to the sched-
uled visits on days 1 and 3, caregivers of newborns are
requested to inform the study team if they notice any
unexpected clinical signs or behaviour changes in the
baby within three days after supplementation. Newborns
who have any adverse events are referred to the nearest
health facility and managed as per standard of care of
the Ministry of Health.
Follow up during infancy Village-based FWs follow up
enrolled infants by monthly home visits from 1 through
12 months of age. At each follow up visit, mortality
events are noted and communicated to the team that
conducts a verbal autopsy interview. Any hospitaliza-
tions between follow up visits are recorded. Data are
collected on the infants’ feeding and immunization sta-
tus at each visit.
Blood samples Serum samples are collected over a full
calendar year (April 2011 to April 2012). Samples are
collected from a subsample of infants aged 2 weeks and
3 months and the mothers of the 3 month old infants.
The mothers and infants are randomly selected from
the study data base using a computer generated random
number list. All samples are analysed for serum retinol,
retinol binding protein concentrations and C reactive
protein.
Data management Paper based forms are used to col-
lect data in the field. These forms are checked by senior
staff on a weekly basis and the forms are transferred to
the central office every week and double entered. A
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has in built verification, range and consistency and inter
data base checks. This system also generates listings of
the work load for each FW each week.
Central cleaning of the data at KHRC is performed
weekly, including running additional range and consis-
tency checks and periodic reviews of distributions and
identification of outliers. Cleaned data are merged
weekly with the master data set. Weekly reports are pro-
vided to the trial PIs and merged data are provided on a
monthly basis to WHO.
India
Study setting The study is being conducted in rural
sites of Faridabad and Palwal districts, in the state of
Haryana, India. The population of the two districts is
~2.1 million. Based on data obtained from a previous
trial in the area, the birth rate in this population is 25
per thousand, the infant mortality 60 per thousand live-
births per year and the less than six month mortality
rate is 50 per thousand live-births per year.
The HIV prevalence among women attending antenatal
care in Haryana in the year 2006 was estimated to be
0.13% [22]. Vitamin A deficiency is likely to be a problem
in mothers and young children. The prevalence of subcli-
nical vitamin A deficiency based on serum retinol < 20 μg/
dl in children aged 3 to 6 years was recently reported as
14.2% [23]. Prevalence of signs and symptoms of vitamin
A deficiency among children 5 to 9 years and 10 to 14
years in Haryana was reported to be 15 and 25 per thou-
sand respectively [24]. During the study implementation
period there are no programs or research on micronutri-
ents or maternal vitamin A supplementation ongoing in
the area. The national program recommends 6 monthly
doses of vitamin A (100,000 IU) starting at 9 months of
age; the percentage of children 12-35 months of age given
vitamin A in the last 6 months in Haryana was 15.9% [25].
In the study areas, around half the families are nuclear; the
median number of family members is 6 (5, 8). Around half
(52%) of mothers of young children have never been to
school; 95% of women do not work outside home. The
median (range) family income per year in Year 2010 was
Indian Rupees 36,000 (600 to 4600000). The most com-
mon sources for seeking care for ill children are private
practitioners within and outside of the villages (~ 60%).
Over half the deliveries are conducted at home by tradi-
tional birth attendants and over 35% of infants are born
low birth weight (< 2500 g). Around 40% of under twos
have < -2 HAZ and 17% have WHZ score < -2 [26].
Identification of newborns The study team met com-
munity leaders, government health workers, Accredited
Social Health Activists (ASHAs), Anganwadi Workers
(AWWs) and Auxiliary Nurse Midwives (ANMs) and
explained the purpose of the study to them. Study FWs
identify pregnant women in areas allocated to them and
follow them until outcome occurrence. They report
births to the study coordinators. She/he allots the births
to workers from the enrolment team.
Screening and enrolment At enrolment, the workers
explain the study to the family and in those willing,
written consent is obtained from the parents of the
infant. The infant is given the dose of vitamin A/placebo
and forms containing baseline socioeconomic character-
istics, information on feeding practices and weight of
the infant and mother dietary questionnaires are filled
in net books. The family is given a card containing tele-
phone numbers of the study physicians for any further
information on the study.
Monitoring of potential adverse events After enrol-
ment, each infant is visited by the enrolment team at
hospital or home 1 day and 3 days after supplementa-
tion to ascertain adverse events. Newborns with adverse
events are referred/escorted to the nearest health facility
for management.
Follow up during infancy Each enrolled infant is allo-
cated to a home visit worker (contiguous study areas are
allocated to FWs in advance) for further follow up visits
till 12 months of age. All infants are contacted when
aged 1, 3, 6 and 12 months by the home visit worker to
document vital status, hospitalization, immunization,
and information on feeding practices. Verbal autopsies
are conducted to ascertain causes of deaths reported.
Whenever hospital records are available these are photo-
copied and attached to the form. A hospitalization is
defined as either an inpatient admission (where an
infant receives an inpatient slip with a registration num-
ber and is allotted a bed) or a stay of ≥ 6 hours duration
in the hospital including the emergency services, diar-
rhoea management room or any paediatric wards of the
institution.
Blood samples Blood specimens are being obtained
from a subsample of infants at 2 weeks and mother
infant pairs at 3 months for serum retinol, retinol bind-
ing protein concentrations and C- reactive proteins.
Specimens will be collected over one calendar year and
during one week every month. The study areas have
been divided into four quadrants. Every month a blood
specimen is requested from 60 randomly selected infants
aged 2 weeks (up to +6 days) and 60 mother-infant pairs
(infant aged 3 months up to +6 days) residing in one
quadrant.
Data management All data are captured electronically
in net books. The data management centre is set up in
the field office rented in the field sites. Range and logi-
cal checks are incorporated and cleaned data are sent to
WHO every month.
Tanzania
Study setting The study is being conducted in both
urban and rural areas in Tanzania. In Dar es Salaam,
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ities and their respective catchment areas. In Morogoro
region, the study is carried out in Ifakara town and sur-
rounding rural Kilombero, Ulanga and Kilosa districts
nested within a demographic and health surveillance
system. There are approximately 2.5 million people liv-
ing in Dar es Salaam and 400,000 in Ifakara and sur-
rounding areas. The 2004-05 Tanzania Demographic
and Health Survey [27] estimated the infant mortality
rate at 73 per 1000 live births in urban areas and 85 per
1000 live births in rural areas. The prevalence of Vita-
min A deficiency for infants at age 6 months was
reported to range from 26% to 41%.
Identification of newborns Newborns are identified as
part of a pregnancy and birth surveillance system or
when an infant is born in selected labour wards in the
study areas. Women recruited during pregnancy, either
during routine antenatal care or through regular house-
hold visits conducted as part of the demographic and
health surveillance system, are consented and followed
closely during pregnancy. Information about household
demographics, nutritional status, and pregnancy compli-
cations are collected during this time. For women
recruited at labour wards, the same information is col-
lected in the week following birth. For women recruited
as part of pregnancy surveillance, births are identified by
routine follow up by field staff, by village-based key
informants, or because women self-report their own
birth. All infants born in selected labour wards in the
study areas are screened for enrolment.
Screening and enrolment After the birth of a live
infant, parents are asked for consent to participate in
the study. Those who give written informed consent are
screened to determine if the infant meets the eligibility
criteria. Those consenting and eligible are given a single
dose of 50,000 IU of vitamin A or placebo. The number
written on the blister pack of vitamin A or placebo
becomes the infant’s ID, and an identity card is issued.
Infants are randomized individually within the geogra-
phical strata according to a computer-generated random
number list, arranged in blocks of 20, in which unique
identification numbers corresponds to one of the two
interventions. Each new infant is assigned the next avail-
able study number. Previous experience has demon-
strated feasibility to conduct the individually
randomized controlled trial in these study clinics and
communities.
Monitoring of potential adverse events Trained FWs
visit enrolled infants at home one day and three days
after dosing to monitor possible side effects of vitamin
A supplementation. A standard form is completed docu-
menting symptoms of potential side effects. For each
infant, reported symptoms including bulging fontanelle,
diarrhoea, vomiting, fever, inability to suck or feed, and
convulsions are recorded. In addition, caregivers of new-
borns are asked if they notice any unexpected clinical
signs or behaviour changes in the baby since the time of
supplementation. If a problem is reported, study staff
refers the family to the nearest health facility, where any
morbidity is managed per the standard of care estab-
lished by the Ministry of Health in Tanzania.
Follow up during infancy F i e l ds t a f fv i s i tt h eh o m eo f
enrolled infants at 1 month, 3 months, 6 months, and
12 months after birth. The main purpose of the visits is
to ascertain survival status during infancy. Additionally,
information about symptoms of illness in the past
month (cough, refusal to eat, fever, difficulty breathing,
chest retraction, convulsions, vomiting, and diarrhoea)
and any past morbidity that resulted in hospitalization
are collected. For hospitalizations, detailed information
is sought from medical records or mother’s report about
the date of admission, length of hospital stay, and the
reason for admission.
During the visits, FWs assess if the child is alive and
still a resident in the study area. Key informants within
the demographic surveillance areas also ascertain vital
status and report it to the study team. In case of a death
of a study child, the event is documented, and trained
field staff completes a verbal autopsy with the child’s
primary caregiver. For women who travel out of study
area, attempts to maintain contact with her through cell
phone or relatives in the area are made in order to col-
lect information on the child’s vital status.
Blood sample A blood sample is requested from 728
infants at 2 weeks of age, and samples are also requested
from 728 mother-infant pairs at 3 months postpartum.
The samples are collected over the course of one year
to cover all seasons, and specific geographical zones are
sampled on a rotating basis in order to facilitate logis-
tics. Thus, every week 14 infants that meet the age
requirements and live within the designated geographi-
cal area are randomly selected. Samples are centrifuged,
and serum aliquots are frozen until testing of samples.
Data management Data are captured electronically
using touch screen tablet PCs and net books. Software
for real-time data entry has detailed range and consis-
tency checks to ensure data quality. Data are uploaded
to the main server in Dar es Salaam via the cell network
or wireless internet where possible. Data are further
reviewed by data management team, and identified dis-
crepancies are resolved by site supervisors or the field
coordinator. Data are uploaded each month to WHO.
Standardization and quality assurance of the three
studies
Data collection instruments
Across the three studies, there are shared questionnaires
that each contains a set of “core” variables collected by
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analyses. Each core variable has a standard definition,
acceptable range limits, and is maintained in agreed
upon data formats.
Training and standardization
Research staff of all three studies has been carefully
trained to conduct surveillance, interview families,
obtain informed consent, administer the intervention/
placebo capsules, collect baseline and follow up informa-
tion and in electronic data capture (India and Tanzania).
Supervision and quality checks
To ensure quality of data, spot checks are done for each
FW at least once a month to confirm whether the work-
ers are visiting families. Workers who have conducted a
home visit in the last 6 days are selected and families
are called or visited to confirm whether the worker had
visited them.
Additionally supervised visits are conducted for each
worker once a month to assess and improve the quality
of activities done by the worker. Different activities
(consenting, screening, capsule administration, post dos-
ing and follow up visits) conducted by workers are
observed by supervisors by accompanying FWs on these
visits. Each worker is accompanied at least once a
month. During supervised visits the following aspects
are evaluated; worker appearance and quality of interac-
tion with the family, whether the questions in the form
are asked correctly and procedures, if relevant (e.g.
weighing and capsule administration), are performed
correctly.
Site monitoring
WHO technical staff conducts at least two monitoring
visits to each site every year. A detailed structured
review of study implementation is done at each visit.
The monitors make direct observations of study imple-
mentation and data management activities. The key
areas that are monitored include the pace of recruit-
ment, consent procedures, storage and use of study sup-
plements, follow up visits, data collection, collection
transport and storage of blood samples and data man-
agement. The recommendations arising from the site
visit are discussed for implementation with the Principal
Investigators.
Data monitoring
Data range and consistency checks are built into the
data entry system and any discrepancies are returned to
the field for verification. Data from all studies are sent
every month to a central data repository which is estab-
lished at WHO. Data quality checks are applied on a
monthly basis and feedback provided to the study sites.
Capsule testing
The vitamin A capsule supplier provided evidence of
rigorous stability testing and the certificates of analysis.
Additionally an independent laboratory checks to
confirm the content of the capsules throughout the
study. Every three months, twenty randomly selected
unused backup capsules are selected from among those
capsule strips used for enrolments in the previous three
months and sent to an independent laboratory for analy-
sis of vitamin A content (VITAS, Norway).
Laboratory standardization
Blood samples are collected, transported and analysed
according to a quality control/assurance protocol to
assure retinol contents within accepted ranges. Labora-
tories performing analysis of blood samples for vitamin
A concentrations participated in the VITAL-EQA pro-
gram from the US Centers for Disease Control and Pre-
vention (CDC) for quality control.
Analysis plan for the three studies
Definitions
T h ep r i m a r yo u t c o m eo ft h es t u d yi sd e f i n e da sad e a t h
between supplementation and 180 days of life (6
months). Secondary mortality outcomes are defined as a
death between supplementation and 28 days of life, and
a death between supplementation and 365 days of life.
Severe morbidity is defined as one or more hospitaliza-
tions due to any illness between supplementation and
day 180 of life. A hospitalization is defined as an admis-
sion to hospital as an inpatient, as reported by the
mother. Infants will only contribute one hospitalization
episode to the analysis, regardless of how many times
they were hospitalized in the first six months of life.
Potential adverse events are defined as specific events
occurring within 3 days of supplementation. These
events include all deaths within 3 days of supplementa-
tion; bulging fontanelle confirmed by the research team
through a physical examination of the infant; or primary
caregiver reports of fever, vomiting, diarrhoea, inability
to suck or feed, or convulsions in the first 3 days post
supplementation.
General principles for analysis
All analyses will be conducted on an intention-to-treat
basis, regardless of whether the infant is known to have
received a full dose or not (for example, if the infants
spit up all or some of the dose). All analyses will be per-
formed with both person time (infant years of follow up)
(primary analysis) and live births as the denominator.
Random effects models and robust standard errors will
be used to account for clustering of deaths with multiple
births.
Separate analysis workshops will take place at the end
of follow up in each of the three study sites. Data clean-
ing for the analysis of all the primary and secondary
outcomes will be completed before the workshops and
the databases will be locked. The randomization code
will be provided to the members of the trial teams dur-
ing the workshop. The code will first be provided as
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completed the code will be provided as allocation
groups (vitamin A and placebo). Analysis will be per-
formed separately by site.
Individual site results will be presented to the DSMB
at a joint meeting within 3 months of analysis in each
site.
Flow of participants
The flow of the number of participants through assess-
ment of eligibility, randomization, follow-up and analysis
will be documented (Figure 2). Reasons for exclusions
and withdrawals will be described.
Comparability of participants in intervention and control
groups
Summary values (means, proportions) for several back-
ground characteristics in the intervention and control
groups will include maternal age, parity, maternal edu-
cation, wealth index of the household, place of delivery,
singleton or multiple birth, sex of infant, birth weight,
median age at supplementation and immunization status
    Assessed for eligibility (n=...)     
     
 
   
          Excluded (n=...): 
- Would not stay for 6m (n=…) 
- Not able to feed (n=…) 
- Declined to participate (n=...) 
- Other reasons (n=...) 
   
             
  Randomised  (n=...)    
     
 
 
 
   
    Allocated to vitamin A (n=...): 
Received vitamin A (n=...) 
Did not receive vitamin A (n=...) 
  Allocated to placebo (n=...): 
Received placebo (n=...) 
Did not receive placebo (n=...) 
   
Loss to followup 
between allocation and 
28d (n=…) 
-Moved (n=…) 
-Withdrawn (n=…) 
         
Loss to followup 
between allocation and 
28d (n=…) 
-Moved (n=…) 
-Withdrawn (n=…) 
    Vital status known at 28d  
(n=x1+x2) 
Alive at 28d (n=x1) 
Died between allocation and 28d 
(n=x2)  
Infant years of followup (n=…) 
  Vital status known at 28d  
(n=x1+ x2) 
Alive at 28d (n=x1) 
Died between allocation and 28d 
(n=x2)  
Infant years of followup (n=…) 
   
Loss to followup 
between 29d and 180d 
(n=…) 
-Moved (n=…) 
-Withdrawn (n=…) 
         
Loss to followup 
between 29d and 180d 
(n=…) 
-Moved (n=…) 
-Withdrawn (n=…) 
    Vital status known at 180d  
(n=x1+x2) 
Alive at 180d (n=x1) 
Died between 29d and 180d  
(n=x2)  
Infant years of followup (n=…) 
  Vital status known at 180d  
(n=x1+x2) 
Alive at 180d (n=x1) 
Died between 29d and 180d 
 (n=x2)  
Infant years of followup (n=…) 
   
Loss to followup 
between 181d and 
365d (n=…) 
-Moved (n=…) 
-Withdrawn (n=…) 
          Loss to followup 
between 181d and 
365d (n=…) 
-Moved (n=…) 
-Withdrawn (n=…) 
    Vital status known at 365d 
 (n=x1+x2) 
Alive at 365d (n=x1) 
Died between 181d and 365d 
(n=x2)  
Infant years of followup (n=…) 
  Vital status known at 365d  
(n=x1+ x2) 
Alive at 365d (n=x1) 
Died between 181d and 365d  
(n = x2)  
Infant years of followup (n=…) 
   
 
 
Figure 2 Structure of the study flow chart.
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Page 9 of 13(time of first DTP immunization). No significance tests
will be performed [28].
Main effects
For the primary outcome, all-cause mortality between
supplementation and 180 days of age, data will first be
analysed using person time, i.e. infant years of follow
up, as the denominator. Hazard ratios and 95% confi-
dence intervals comparing the effect of vitamin A on
deaths in the first half of infancy between vitamin A and
placebo groups will be calculated using Cox regression.
In the unlikely event that there is imbalance between
the treatment and control groups, the final statistical
models will include adjustment for all imbalanced vari-
ables. The effect of vitamin A supplementation on all-
cause mortality between supplementation and 180 days
of age will also be assessed using enrolled infants as the
denominator. The principles outlined above will be fol-
lowed, and logistic regression will be used to compare
mortality in the vitamin A and placebo arms.
The effect of vitamin A supplementation on secondary
outcomes (all-cause mortality from supplementation to
12 months, all-cause mortality from supplementation to
end of the neonatal period, hospitalizations) will be
assessed using similar methods to the primary analysis;
both person time and enrolled infants will be used as
denominators for all analyses.
Adverse events
Adverse events in the vitamin A and placebo groups will
be tabulated [29]. The denominator will be all enrolled
infants. The absolute risk of an adverse event per arm
and per adverse event type will be presented.
Sub-group analyses
The sub-group analyses listed below were specified a
priori in the trial protocol.
The effect of vitamin A supplementation on all-cause
infant mortality from 6 to 12 months by:
- Birth weight (< 1.5 kg, 1.5-1.9 kg, 2.0-2.4 kg, ≥ 2.5
kg, and as a continuous variable)
- Sex (male or female)
- Risk of death before and after receipt of first dose of
DTP vaccine. For this analysis, person-time for each
infant will be divided into before and after receiving
DTP vaccine.
- Economic group (richest to poorest wealth quintiles,
using principal components analysis)
- Maternal large-dose vitamin A supplementation
(received or not received)
Site-specific results will be presented for all subgroups.
Statistical interactions will be assessed using likelihood
ratios tests for unadjusted hazard ratios or Wald tests for
adjusted hazard ratios. If significance tests yield a p value
< 0.01 then site specific mortality rates and hazard ratios
comparing mortality in the vitamin A supplementation
and placebo group in each sub-group will also be reported.
Serum retinol analyses
The effect of vitamin A supplementation on vitamin A
status will be assessed on a sub-sample of infants at 2
weeks (to establish whether there has been a short term
improvement in vitamin A status) and 3 months (to
establish whether there has been a longer term improve-
ment in vitamin A status). Mean serum vitamin A and
retinol binding protein concentrations at each site will
be compared in the vitamin A and placebo groups using
independent sample t-tests for the overall sample. If the
distributions are found to be skewed, the mean log con-
centrations will be compared. Further analyses will be
conducted in which retinol levels will be adjusted for
CRP, which is a biochemical marker of infection. Mater-
nal serum retinol concentrations will be analysed to
assess the prevalence of maternal vitamin A deficiency.
Interim analyses by the DSMB
Ac o m m o nD S M Bh a sb e e ns e tu pt om o n i t o rt h ep r o -
gress of the three trials. The DSMB is responsible for
monitoring and assessing the safety of the trial and con-
sists of an epidemiologist, a statistician and a clinician/
social scientist from each of the three study sites. It
meets every six months, and all three trials are discussed
at the same meeting. The DSMB examines adverse
events and deaths within 3 days of supplementation
every 3 months. In addition ,t h e r ew i l lb et w of o r m a l
interim analyses of mortality to six months for each site.
The first interim analysis will take place when approxi-
mately one third of participants have reached six
months of age and the second interim analysis will take
place when approximately half of the participants have
reached that point.
The analysis by DSMB is conducted in a blinded man-
ner (treatment groups X and Y). The randomization
code will be broken if there is clear evidence of a differ-
ence in mortality between the two arms. A trial will be
stopped if there is early evidence of a significantly lower
mortality in the vitamin A group compared with placebo
according to P values specified in the O’Brien- Fleming
rules [30]. For the first interim analysis, a P value of <
0.001 is specified; for the second, the specified P value is
< 0.015. Only the trial centre showing increased or
decreased mortality with these specified p values will be
stopped; the other trial centre/s will continue until the
next interim analysis or the final analysis as appropriate.
For the final analysis for each site, an increase or
decrease in mortality in either group will be considered
significant if the P value is < 0.047; this lower value is
specified to account for the fact that the data will have
been examined twice before the final analysis [30].
Timelines
Enrolment of participants started between June and
August 2010 in the three studies and is likely to be
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pleted, follow up visits will continue to be conducted for
a period of 6 months. This will ensure that all enrolled
i n f a n t sh a v eac h a n c et oc o m p l e t et h e i r6m o n t hf o l l o w
up. A proportion of enrolled infants will therefore have
less than 12 months follow up.
Discussion
The three ongoing studies described in this paper are
the largest studies evaluating neonatal vitamin A and
are expected to provide definitive information to help in
formulating policy in favour of or against this interven-
tion. All studies are individually randomized, double
blind placebo controlled trials. Each is individually pow-
ered to detect a moderate but important effect on mor-
tality in enrolled infants.
The studies are being conducted in Ghana, Tanzania
and India and combined with previous studies (con-
ducted in Indonesia, Bangladesh, Nepal, India, Guinea-
Bissau and Zimbabwe), will provide information general-
izable to Africa and South Asia. There are very few
exclusion criteria because the studies are expected to
answer a pragmatic question about the effect of routine
use of neonatal vitamin A.
The intervention is a single dose of 50,000 interna-
tional units within the first three days of life, consistent
with the previous studies that have tested this interven-
tion. The comparison is placebo with blinding achieved
through numbered supplements. This is the most robust
design available to ascertain efficacy of an intervention.
The primary outcome for this study was chosen to be
mortality in the period from supplementation to 6
months of age. This was done because there is a policy
on vitamin A supplementation in the second half of
infancy in many developing countries, and the effects of
the intervention (neonatal vitamin A supplementation)
will be changed by this large supplement provided in
the second half of infancy. However, two previous stu-
dies from Guinea-Bissau have suggested that the inter-
vention may have a negative effect in the second half of
infancy. Therefore, we have added mortality from sup-
plementation until 12 months of age as a secondary out-
come in consultation with the DSMB of the study.
We have several subgroup analysis decided ap r i o r i .
These subgroup analyses are planned to confirm or
refute hypotheses raised by previous studies and sys-
tematic reviews. A pooled analysis of two studies from
Guinea-Bissau raised the hypothesis that the interven-
tion may have a negative effect in girls, but a meta-ana-
lysis of all available trials did not find this interaction.
The studies from Guinea-Bissau have also raised the
hypothesis that effects may be different before or after
the first dose of DTP immunization. A meta-analysis
hypothesized that the effects may be different in low or
normal birth weight infants and by the level of vitamin
A deficiency in populations.
The biological rationale for the potential effect of neo-
natal vitamin A is not known. It has been hypothesized
that the intervention could work through positively
affecting the immune system or by promoting the
maturation and integrity of the epithelium. A set of par-
allel animal and human studi e si sb e i n gc o n d u c t e dt o
understand the transport and metabolism of the neona-
tal vitamin A dose and its effects on the innate and
adaptive immune system. These studies will shed more
light on the potential biological mechanisms through
which this intervention may work.
However, policy formulation will largely be based on
the results of efficacy of the intervention from the
ongoing randomized controlled trials. These results will
be combined with results of previous studies in a new
meta-analysis for an overall effect. The data from the
three new studies, as well as previous studies if possible,
will be pooled to carefully examine subgroup effects.
Trial status
The trials are ongoing. Participant recruitment is
expected to be completed by September 2012.
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